Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib plus Irinotecan in Advanced Gastric Cancer
NCT05643677Phase 2Unknown
- Sponsor
- Fujian Medical University
- Start
- Dec 2022
- Primary completion
- Nov 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of fruquintinib in gastric cancer (GC), sponsored by Fujian Medical University. Status: unknown.
02
Drugs
fruquintinib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05643677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05643677.